Next Article in Journal
Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer
Next Article in Special Issue
Hippo Pathway in Cancer, towards the Realization of Hippo-Targeted Therapy
Previous Article in Journal
Clinical Impact of Epithelial-to-Mesenchymal Transition Regulating MicroRNAs in Pancreatic Ductal Adenocarcinoma
Previous Article in Special Issue
Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Cancers 2018, 10(9), 329; https://doi.org/10.3390/cancers10090329

Repurposing of Drugs Targeting YAP-TEAD Functions

1
Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
2
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
3
Department of Life Sciences, University of Modena and Reggio Emilia, Unit of Pathology, 41124 Modena, Italy
4
Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy
5
Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy
*
Author to whom correspondence should be addressed.
Received: 4 August 2018 / Revised: 7 September 2018 / Accepted: 7 September 2018 / Published: 14 September 2018
Full-Text   |   PDF [5029 KB, uploaded 14 September 2018]   |  

Abstract

Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway’s terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds. View Full-Text
Keywords: Hippo pathway; YAP-TEAD disruption; drug repurposing; cell signaling; protein-protein interactions Hippo pathway; YAP-TEAD disruption; drug repurposing; cell signaling; protein-protein interactions
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Elisi, G.M.; Santucci, M.; D’Arca, D.; Lauriola, A.; Marverti, G.; Losi, L.; Scalvini, L.; Bolognesi, M.L.; Mor, M.; Costi, M.P. Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers 2018, 10, 329.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top